Le Lézard
Classified in: Ebola virus, Business
Subject: SVY

$65 Billion Market in Medical Laboratory Tests


ROCKVILLE, Md., Sept. 5, 2018 /PRNewswire/ -- In vitro diagnostic tests, or non-imaging laboratory tests that doctors use to make critical health decisions, represent a $65 billion and growing healthcare market. Hundreds of companies participate, though key firms such as Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers and Danaher dominate. This according to market research firm Kalorama Information, a New York City-based research firm that focuses on biotechnology and in vitro diagnostics, or IVD. Kalorama just released its 1800+ page market study, The Worldwide Market for In Vitro Diagnostics, 11th Edition.

Kalorama Information Logo.

Why is this market growing? Kalorama says threats to human health continue - obesity, diabetes, cancer, cardiac disease and infectious diseases, worldwide. These situations have created demand for highly specific, sensitive and sometimes expensive tests. IVD companies spend a lot more than other industries on research, and this fuels new testing products. Is there any limit to growth? Kalorama says that there are limits because testing is regulated by governments worldwide, and test reimbursements in developing countries are often reduced. 

"It's a paradox of sorts. As great technologies come out, as new genomics, microfluidics and IT appear, the appetite of world healthcare systems to pay for tests decreases," said Bruce Carlson.  "What's the way around it? Even more innovation, and public pressure for test funding, for starters. But even without any action on the industry's part, demand is fueled by aging world populations and disease trends." 

These specialized tests have come under scrutiny from payers and regulatory authorities. The study balances out regulations and payor information with new product innovations, disease statistics and clinical practice to arrive at market estimates. Kalorama surveys vendors and reviews published facts and medical journals in making assessments. The firm thinks in vitro diagnostics grow at 4% overall ? but that average is brought down by mature industries within IVD. There are biomarker segments that will double in 5-7 years, according to the report.

"Cancer and infectious disease lead growth," said Bruce Carlson, Publisher of Kalorama Information. "But we are closely watching the infectious disease categories in the wake of PAMA cuts and European lab consolidation and payment slowdowns."

Nevertheless, the market for IVD products is in good shape overall, according to the report. The market improved generally since the last edition of Kalorama's worldwide in vitro diagnostics report. 

The next five to ten years or so will see moderate and gradual change in IVD product markets.  IVD manufacturers can expect:

Infectious diseases are a category to watch in IVD, said Carlson. "Chagas, dengue, chikungunya and other emerging infectious diseases, along with the well-known Ebola and Zika virus have brought a reality that tropical infectious diseases know no borders."

But these aren't the only areas where testing is set to grow.

"Every time you hear about a significant health issue in the United States or worldwide, it's likely that testing has a role," Carlson said. "Substance abuse and opioids? Testing is helping there.  Over prescription of antibiotics? Testing is helping there. Reducing hospital stays? There again, testing can aid."

About Kalorama Information

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.

We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website: https://www.kaloramainformation.com/.   

Press Contact:                                                         
Bruce Carlson
212 807 2262
[email protected]

 

SOURCE Kalorama Information


These press releases may also interest you

21 mar 2019
The "Europe Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Welding is one of the critical processes employed in the manufacturing...

21 mar 2019
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...

20 mar 2019
Merck , known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies' broad, strategic collaboration...

20 mar 2019
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND NOTICE Shareholders who wish to...

20 mar 2019
The Oslo Business for Peace Award is given to inspiring business leaders who have put society first. 2019's winners are: Dr Agbor Ashumanyi Ako, medical director of GiftedMom, Alice Laugher, CEO of Committed to...

19 mar 2019
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...



News published on and distributed by: